Health Sector Down As Report of Industry Price Collusion Surfaces

U.S. stocks were down slightly on Thursday as the S&P 500 maintains its longest losing streak since the financial crisis in 2008. The healthcare sector fell the most at 1.10%.

Two of the most active players, Teva Pharmaceutical Industries  (TEVA) and Pfizer  (PFE) , drove down the sector. Shares of Teva Pharmaceutical Industries fell almost 10% to $39.20 after Bloomberg reported that the Israel-based company has received subpoenas for its suspected role in price collusion with other generic pharmaceutical companies.

New York-based drug-maker Pfizer reported worse-than-expected third-quarter profit of 61 cents a share on Tuesday. It also announced a surprising end to the late-stage development of an experimental cholesterol-lowering drug. Shares of Pfizer decreased 2.42% to $29.89 today.

The Dow Jones Industrial Average lost 29 points, or 0.16%, down to 17,930. The S&P 500 index fell 9 points, or 0.44%, to 2,088, and the Nasdaq composite declined about 47 points, or 0.92%, to 5,058.

The biggest losers of the day were Achillion Pharmaceuticals  (ACHN) , Pacific Biosciences of California (PACB) , Impax Laboratories  (IPXL) , Akorn  (AKRX) and Insmed  (INSM) . 

New Haven, CT.-based biopharmaceutical company Achillion Pharmaceuticals reported a net loss of $20.7 million, or 15 cents per share, compared with net income of $26.3 million (19 per share) for the third quarter of 2015 in its third quarter earnings release today. Shares of Achillion tumbled almost 29% to $4.32 by the closing bell.

Menlo Park, CA.-based genetic-sequencing company Pacific Biosciences of California announced its third quarter earnings after the market closed on Wednesday. The company reported revenue totaled $25.1 million, up 80% compared to $13.9 million for the third quarter of 2015. Despite that, shares Pacific Biosciences of California dipped almost 20% to $6.65 per share at the market's close. 

Shares of Hayward, CA.-based Impax Laboratories Inc fell almost 20% to $16.50. The specialty pharmaceutical company is set to release its third quarter earnings on Nov. 9.

Akorn, another specialty pharmaceutical company, saw its shares drop about 18% to $20.27 despite reporting a net revenue of $284 million for the third quarter 2016, an 11% increase year-over-year. 

Shareholder rights law firm Robbins Arroyo recently took a class action complaint was filed against Akorn for alleged violations of the Sherman Antitrust Act and the Clayton Antitrust Act by Akorn's officers and directors. A press release from the law firm accused Akorn of price collusion with its competitors that caused certain drug prices to spike nearly 700%.

Bridgewater, NJ.-based biopharmaceutical company Insmed shares fell almost 14% to $10.36 after posting third quarter 2016 today. The company reported a net loss of $37.8 million, or $0.61 per share, compared with a net loss of $31.0 million, or $0.50 per share, for the third quarter of 2015.

More from Stocks

The Easy Money in Amazon Stock Has Been Made

The Easy Money in Amazon Stock Has Been Made

Is the Cannabis Crazy Equivalent to the Dot Com Bubble?

Is the Cannabis Crazy Equivalent to the Dot Com Bubble?

Get a Juicy 8%+ Dividend Yield With Solid Income Streams All in One Stock

Get a Juicy 8%+ Dividend Yield With Solid Income Streams All in One Stock

U.S.-Chinese Trade War Could Mash Up Apple

U.S.-Chinese Trade War Could Mash Up Apple

How to Overcome the Fear of Trading Super-Momentum Stocks

How to Overcome the Fear of Trading Super-Momentum Stocks